David Brian Horwitz

US Patent:

6495521, Dec 17, 2002

Filed:

Jan 17, 2001

Appl. No.:

09/764838

Inventors:

David L. Horwitz - Hillsborough CA

Assignee:

SciClone Pharmaceuticals, Inc. - San Mateo CA

International Classification:

A61K 3800

US Classification:

514 12, 4242781, 424500, 424300, 424399, 424514, 424 2, 424 12, 424 45, 424262

Abstract:

The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which are effective in inhibiting DNA synthesis or DNA polymerase during replication of the hepatitis B virus.

US Patent:

7118746, Oct 10, 2006

Filed:

May 12, 2000

Appl. No.:

09/979813

Inventors:

Gail K. Naughton - Del Mar CA, US
David L. Horwitz - San Diego CA, US
Mark A. Applegate - San Diego CA, US
Joan Zeltinger - San Diego CA, US
Jonathan N. Mansbridge - La Jolla CA, US
Andreas Kern - San Diego CA, US
Lee K. Landeen - San Diego CA, US
Anthony Ratcliffe - Del Mar CA, US
R. Emmett Pinney - Poway CA, US

Assignee:

SkinMedica, Inc. - Carlsbad CA

International Classification:

A61K 38/17
C12N 5/08
C12N 5/22

US Classification:

4241841, 4241981, 424423, 435 703, 435 691, 435325, 435391, 435395, 435408, 514 1

Abstract:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

US Patent:

7824333, Nov 2, 2010

Filed:

Mar 31, 2006

Appl. No.:

11/395024

Inventors:

Erik Otto - San Francisco CA, US
David Horwitz - Los Altos CA, US
Kirk Harmon - San Ramon CA, US
Manoj Sharma - Milpitas CA, US

Assignee:

LifeScan, Inc. - Milpitas CA

International Classification:

A61B 5/00

US Classification:

600365

Abstract:

The present invention relates to methods and systems for monitoring the effectiveness of diabetes treatment. Methods and systems in accordance with the present invention provide information relating to variability of glucose levels and hypoglycemia and hyperglycemia. Such information is based on time-stamped blood glucose data obtained from a meter or the like and actual measurements of HbA1c levels are not required.

US Patent:

8138147, Mar 20, 2012

Filed:

Jan 6, 2009

Appl. No.:

12/349451

Inventors:

Gail K. Naughton - Del Mar CA, US
David L. Horwitz - San Diego CA, US
Mark A. Applegate - San Diego CA, US
Joan Zeltinger - San Diego CA, US
Jonathan N. Mansbridge - La Jolla CA, US
Andreas Kern - San Diego CA, US
Lee K. Landeen - San Diego CA, US
Anthony Ratcliffe - Del Mar CA, US
R. Emmett Pinney - Poway CA, US

Assignee:

Skinmedica, Inc. - Carlsbad CA

International Classification:

A61K 38/18
C12N 5/02

US Classification:

514 81, 435406, 435325, 435387, 514 92, 514 188

Abstract:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

US Patent:

8361485, Jan 29, 2013

Filed:

Oct 3, 2006

Appl. No.:

11/538380

Inventors:

Gail K. Naughton - Del Mar CA, US
David L. Horwitz - San Diego CA, US
Mark A. Applegate - San Diego CA, US
Joan Zeltinger - San Diego CA, US
Jonathan N. Mansbridge - La Jolla CA, US
Andreas Kern - San Diego CA, US
Lee K. Landeen - San Diego CA, US
Anthony Ratcliffe - Del Mar CA, US
R. Emmett Pinney - Poway CA, US

Assignee:

SkinMedica, Inc. - Carlsbad CA

International Classification:

A61K 38/00
A61P 17/00

US Classification:

424401, 514 186, 514 188

Abstract:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

US Patent:

8439837, May 14, 2013

Filed:

Oct 30, 2007

Appl. No.:

11/928560

Inventors:

Sharbel E. Noujaim - Menlo Park CA, US
David Horwitz - Los Altos CA, US
Manoj Sharma - Milpitas CA, US
Joseph Marhoul - San Jose CA, US

Assignee:

LifeScan, Inc. - Milpitas CA

International Classification:

A61B 51/14532
A61B 51/14503

US Classification:

600365, 600373

Abstract:

The present invention is directed to a method of reducing false readings in a hypoglycemic detector that includes establishing a predetermined hypoglycemic threshold, a predetermined critical threshold, a predetermined rate of change in glucose concentration where the predetermined critical threshold is below the predetermined hypoglycemic threshold. A first sampling rate is then calculated based upon said predetermined hypoglycemic threshold, said predetermined critical threshold, and said predetermined rate of change in glucose concentration.

US Patent:

8476231, Jul 2, 2013

Filed:

Mar 9, 2012

Appl. No.:

13/417017

Inventors:

Gail K. Naughton - Del Mar CA, US
David L. Horwitz - San Diego CA, US
Mark A. Applegate - San Diego CA, US
Joan Zeltinger - San Diego CA, US
Jonathan N. Mansbridge - La Jolla CA, US
Andreas Kern - San Diego CA, US
Lee K. Landeen - San Diego CA, US
Anthony Ratcliffe - Del Mar CA, US
R. Emmett Pinney - Poway CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A61K 38/18
C12N 5/02

US Classification:

514 81, 514 92, 514 186, 424 851, 424 852, 435325

Abstract:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

US Patent:

20100016700, Jan 21, 2010

Filed:

Jul 17, 2009

Appl. No.:

12/505007

Inventors:

Zara Sieh - Pleasanton CA, US
David Horwitz - Los Altos CA, US
David Price - Pleasanton CA, US
Peter Krulevitch - Pleasanton CA, US
Donna Savage - Rolling Hills Estates CA, US
Robert Shartle - Arnold CA, US

Assignee:

LifeScan, Inc. - Milpitas CA

International Classification:

A61B 5/00
G06F 3/048
H04L 9/32
G08B 1/08
G06F 15/16
G06N 5/02

US Classification:

600365, 715810, 726 16, 34053912, 709202, 709206, 706 54

Abstract:

Various embodiments of a diabetes management system are provided. One exemplary system may include an analyte measurement device and a therapeutic agent delivery device. The measurement device includes a measurement unit, display, and first wireless module. The therapeutic agent delivery device has a delivery device housing, delivery mechanism disposed in the housing that delivers a dosage of the agent to the user upon actuation by the user or health care provider, and a second wireless module. The second module, automatically, without prompting from a user or any active input or action by the user, transmits a signal to the first wireless module indicative of: (a) type of therapeutic agent delivered; and (b) amount of therapeutic agent delivered to the user; or (c) type of therapeutic agent device from which the therapeutic agent was administered. Also described are diabetes management devices and methods.